Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
47.6M
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
49.3M
-
Shares change
-
+10.8M
-
Total reported value, excl. options
-
$1.46B
-
Value change
-
+$336M
-
Put/Call ratio
-
0.72
-
Number of buys
-
86
-
Number of sells
-
-29
-
Price
-
$29.70
Significant Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) as of Q3 2025
141 filings reported holding RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q3 2025.
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.3M shares
.
Largest 10 shareholders include TRV GP V, LLC (7.14M shares), FMR LLC (6.92M shares), ARCH Venture Management, LLC (3.73M shares), Capital International Investors (3.4M shares), Cormorant Asset Management, LP (3.19M shares), GOLDMAN SACHS GROUP INC (2.42M shares), Sofinnova Investments, Inc. (1.95M shares), JOHNSON & JOHNSON (1.78M shares), VANGUARD GROUP INC (1.63M shares), and BlackRock, Inc. (1.57M shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.